155.00
+0.5(+0.32%)
Currency In USD
| Previous Close | 154.5 |
| Open | 154 |
| Day High | 157 |
| Day Low | 154 |
| 52-Week High | 162 |
| 52-Week Low | 49 |
| Volume | 112,891 |
| Average Volume | 166,060 |
| Market Cap | 5.41B |
| PE | -80.73 |
| EPS | -1.92 |
| Moving Average 50 Days | 121.8 |
| Moving Average 200 Days | 78.89 |
| Change | 0.5 |
If you invested $1000 in Belite Bio, Inc (BLTE) since IPO date, it would be worth $14,636.45 as of December 24, 2025 at a share price of $155. Whereas If you bought $1000 worth of Belite Bio, Inc (BLTE) shares 2 years ago, it would be worth $3,377.64 as of December 24, 2025 at a share price of $155.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Belite Bio Announces Pricing of $350.0 Million Underwritten Public Offering of American Depositary Shares
GlobeNewswire Inc.
Dec 02, 2025 3:37 AM GMT
SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have signifi
Belite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares
GlobeNewswire Inc.
Dec 01, 2025 9:20 PM GMT
SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have signifi
New Hope for People Living with a Disease Once Deemed Untreatable: Belite Bio Announces Positive Topline Results from the Pivotal Global, Phase 3 DRAGON Trial of Tinlarebant in Adolescents with Stargardt Disease
GlobeNewswire Inc.
Dec 01, 2025 11:00 AM GMT
Tinlarebant is the first therapeutic candidate to demonstrate clinical efficacy in a global Phase 3 trial for Stargardt disease, achieving a statistically significant p-value of 0.0033Tinlarebant met the primary efficacy endpoint, demonstrating clini